NCT02792816

Molecular Surveillance of Artemisinin Resistance Malaria in Myanmar

A Multi-site Cohort Observational Study for Molecular Assessment of Artemisinin Resistance Falciparum Malaria in Myanmar

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 550 (actual)
• Sponsor: Department of Medical Research, Lower Myanmar · Academic / Other
• Sex: All
• Age: 3 Months – 69 Years
• Healthy volunteers: Not accepted

Summary

Efficacy and safety of the artemisinin combination therapy (ACT) in uncomplicated falciparum malaria patients in Myanmar and artemisinin molecular markers analysis

Detailed description

The investigators assessed the efficacy and safety of the ACT in uncomplicated falciparum malaria in different sentinel sites in Myanmar. The recruited patients were follow-up until day 28 or day-42 based on the ACTs. Day-0 samples were analysed for artemisinin molecular markers, (K13 kelch propeller, Pfmdr2, Pffd and Pfarps10).

Conditions

• Drug Resistance
• Plasmodium Falciparum Malaria

Interventions

Type	Name	Description
DRUG	First line antimalarial in Myanmar (artemether-lumefrantrine, dihydroartemisinin-piperaquine, and artesunate-mefloquine)	Being a observational cohort study, one of the ACT was selected in each study site to assess the efficacy and safety.

Timeline

• Start date: 2009-06-01
• Primary completion: 2013-12-01
• Completion: 2016-05-01
• First posted: 2016-06-08
• Last updated: 2016-06-08

Locations

1 site across 1 country: Burma